13.07.2015 Views

Development of hot-melt extrusion as a novel technique for the ...

Development of hot-melt extrusion as a novel technique for the ...

Development of hot-melt extrusion as a novel technique for the ...

SHOW MORE
SHOW LESS

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

IBU h<strong>as</strong> been reported 22% after 2 hrs [34] . In addition it w<strong>as</strong> observed that incre<strong>as</strong>ed IBUloading (40% - Formulation II) provided f<strong>as</strong>ter rele<strong>as</strong>e rates in contr<strong>as</strong>t to <strong>the</strong> 25% loading(Formulation I). This is attributed to <strong>the</strong> incre<strong>as</strong>ed talc amounts (50%) in Formulation I. Asmentioned earlier talc serves <strong>as</strong> an anti-tacking agent and because <strong>of</strong> its hydrophobic natureretards polymer hydration and <strong>the</strong> subsequent IBU rele<strong>as</strong>e rate. Comparison <strong>of</strong> <strong>the</strong> extruded<strong>for</strong>mulations with <strong>the</strong> Nur<strong>of</strong>en® tablets demonstrated similar rele<strong>as</strong>e rates <strong>for</strong> 25% loadingbut a f<strong>as</strong>ter rate <strong>for</strong> <strong>the</strong> 40% IBU/EPO extrudates. Application <strong>of</strong> a Kruskal-Wallis nonparametrictest (p > 0.05) to <strong>the</strong> results showed no significant difference. Never<strong>the</strong>less, <strong>the</strong>HME extruded <strong>for</strong>mulations showed excellent rele<strong>as</strong>e patterns that could provide f<strong>as</strong>t onsetaction in future clinical trials.4.0 ConclusionsIn this chapter we have demonstrated <strong>the</strong> manufacture <strong>of</strong> robust t<strong>as</strong>te-m<strong>as</strong>ked IBUODTs. For <strong>the</strong> purpose <strong>of</strong> <strong>the</strong> study IBU w<strong>as</strong> <strong>hot</strong>-<strong>melt</strong> extruded and embedded within aEudragit EPO polymer matrix. The in vivo t<strong>as</strong>te-m<strong>as</strong>king evaluation showed that HMEprocessing can be used to m<strong>as</strong>k efficiently <strong>the</strong> t<strong>as</strong>te <strong>of</strong> bitter active substances withoutcompromising tablet palatability. The ODTs developed showed disintegration times andcrushing resistance similar to commercial Nur<strong>of</strong>en® tablets but improved tablet friability.Finally <strong>the</strong> incre<strong>as</strong>ed IBU rele<strong>as</strong>e rates <strong>of</strong> <strong>the</strong> developed ODTs were f<strong>as</strong>ter than <strong>the</strong>commercial Nur<strong>of</strong>en® tablets.5.0 References1. W. Habibh, R. Khankarik, J. Hontz. F<strong>as</strong>t-Dissolve Drug Delivery System. Crit RevTher Drug Carrier Syst. 17 (2000) 61-72.2. D. Douroumis. Practical approaches <strong>of</strong> t<strong>as</strong>te m<strong>as</strong>king technologies in oral solid <strong>for</strong>ms.Expert Opin Drug Deliv. 4 (2007) 417-26.3. A. Mahesh, N. Sh<strong>as</strong>tri, M. Sadanandam. <strong>Development</strong> <strong>of</strong> T<strong>as</strong>te M<strong>as</strong>ked F<strong>as</strong>tDisintegrating Films <strong>of</strong> Levocetirizine Dihydrochloride <strong>for</strong> Oral Use. Curr DrugDeliv. 7 (2010) 21 – 7.4. A. Dinge, M. Nagarsenker. Formulation and evaluation <strong>of</strong> f<strong>as</strong>t dissolving films <strong>for</strong>delivery <strong>of</strong> triclosan to <strong>the</strong> oral cavity. AAPS PharmSciTech. 9 (2008) 349-56.5. Zydis f<strong>as</strong>t dissolving technology(http://www.catalent.com/documents/file/zydis_bro_v15b_Web_MedRES.pdf)60 | P a g e

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!